Heart failure with preserved ejection fraction

Current understandings and challenges

Mads J. Andersen, Barry A Borlaug

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Heart failure (HF) is the leading cause of hospitalization among older adults and the prevalence is growing with the aging populations in western countries. Approximately one-half of patients with HF have preserved ejection fraction (HFpEF). In contrast to HF with reduced EF (HFrEF), there is no proven effective treatment for HFpEF. The pathophysiology of HFpEF is complex, and the dominant mechanisms leading to symptoms of HF often vary between afflicted patients, confounding efforts to apply "one-size fits all" types of therapeutic approaches. Current treatment strategies focus on control of volume status and comorbidities, but future research aimed at individualized therapies holds promise to improve outcomes in this increasingly prevalent form of cardiac failure.

Original languageEnglish (US)
Article number501
JournalCurrent Cardiology Reports
Volume16
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Heart Failure
Therapeutics
Comorbidity
Hospitalization
Population

Keywords

  • Diastolic dysfunction
  • Diastolic heart failure
  • Heart failure
  • Heart failure with preserved ejection fraction
  • Hemodynamics
  • Ventricular function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Heart failure with preserved ejection fraction : Current understandings and challenges. / Andersen, Mads J.; Borlaug, Barry A.

In: Current Cardiology Reports, Vol. 16, No. 7, 501, 2014.

Research output: Contribution to journalArticle

@article{f1fc36471b6140c89ba8fcb379aba6a5,
title = "Heart failure with preserved ejection fraction: Current understandings and challenges",
abstract = "Heart failure (HF) is the leading cause of hospitalization among older adults and the prevalence is growing with the aging populations in western countries. Approximately one-half of patients with HF have preserved ejection fraction (HFpEF). In contrast to HF with reduced EF (HFrEF), there is no proven effective treatment for HFpEF. The pathophysiology of HFpEF is complex, and the dominant mechanisms leading to symptoms of HF often vary between afflicted patients, confounding efforts to apply {"}one-size fits all{"} types of therapeutic approaches. Current treatment strategies focus on control of volume status and comorbidities, but future research aimed at individualized therapies holds promise to improve outcomes in this increasingly prevalent form of cardiac failure.",
keywords = "Diastolic dysfunction, Diastolic heart failure, Heart failure, Heart failure with preserved ejection fraction, Hemodynamics, Ventricular function",
author = "Andersen, {Mads J.} and Borlaug, {Barry A}",
year = "2014",
doi = "10.1007/s11886-014-0501-8",
language = "English (US)",
volume = "16",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "7",

}

TY - JOUR

T1 - Heart failure with preserved ejection fraction

T2 - Current understandings and challenges

AU - Andersen, Mads J.

AU - Borlaug, Barry A

PY - 2014

Y1 - 2014

N2 - Heart failure (HF) is the leading cause of hospitalization among older adults and the prevalence is growing with the aging populations in western countries. Approximately one-half of patients with HF have preserved ejection fraction (HFpEF). In contrast to HF with reduced EF (HFrEF), there is no proven effective treatment for HFpEF. The pathophysiology of HFpEF is complex, and the dominant mechanisms leading to symptoms of HF often vary between afflicted patients, confounding efforts to apply "one-size fits all" types of therapeutic approaches. Current treatment strategies focus on control of volume status and comorbidities, but future research aimed at individualized therapies holds promise to improve outcomes in this increasingly prevalent form of cardiac failure.

AB - Heart failure (HF) is the leading cause of hospitalization among older adults and the prevalence is growing with the aging populations in western countries. Approximately one-half of patients with HF have preserved ejection fraction (HFpEF). In contrast to HF with reduced EF (HFrEF), there is no proven effective treatment for HFpEF. The pathophysiology of HFpEF is complex, and the dominant mechanisms leading to symptoms of HF often vary between afflicted patients, confounding efforts to apply "one-size fits all" types of therapeutic approaches. Current treatment strategies focus on control of volume status and comorbidities, but future research aimed at individualized therapies holds promise to improve outcomes in this increasingly prevalent form of cardiac failure.

KW - Diastolic dysfunction

KW - Diastolic heart failure

KW - Heart failure

KW - Heart failure with preserved ejection fraction

KW - Hemodynamics

KW - Ventricular function

UR - http://www.scopus.com/inward/record.url?scp=84901728615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901728615&partnerID=8YFLogxK

U2 - 10.1007/s11886-014-0501-8

DO - 10.1007/s11886-014-0501-8

M3 - Article

VL - 16

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 7

M1 - 501

ER -